Immunogenicity and therapeutic effects of a Mycobacterium tuberculosis rv2190c DNA vaccine in mice by Yan Liang et al.
RESEARCH ARTICLE Open Access
Immunogenicity and therapeutic effects of
a Mycobacterium tuberculosis rv2190c DNA
vaccine in mice
Yan Liang1†, Xiaoyan Zhang1,2†, Xuejuan Bai1†, Li Xiao1, Xiaomei Wang1, Junxian Zhang1, Yourong Yang1,
Jinying Song1, Lan Wang1 and Xueqiong Wu1*
Abstract
Background: Tuberculosis (TB) is a major global public health problem. New treatment methods on TB are
urgently demanded. In this study, Mycobacterium tuberculosis (MTB) rv2190c DNA vaccine was prepared and
its immunogenicity and therapeutic effects were evaluated.
Results: Non-infected mice immunized with rv2190c DNA or ag85a DNA showed higher levels of interferon-
gamma (IFN-γ) in stimulated spleen lymphocyte culture supernatants, and had more Th1 cells and an
elevatory ratio of Th1/Th2 immune cells in whole blood, indicating that Th1-type immune response was
predominant. Compared with the saline group, ag85a DNA group and rv2190c DNA group in the infected
mice decreased the lung colony-forming units (CFUs) by 0.533 and 0.283 log10, and spleen CFUs by 0.425
and 0.321 log10 respectively, and pathological lesion.
Conclusions: The rv2190c DNA had some immunotherapeutic effect on TB.
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Background
Tuberculosis (TB) is a severe respiratory infectious
disease in which protective immunity and pathological
hypersensitivity to an intracellular bacterium coexist
[1, 2]. In 2013, there were 9 million incident cases
and 1.5 million deaths [3]. It is difficult to cure with
anti-TB chemotherapy because a long treatment dur-
ation (a minimum of six-month chemotherapy) with
multiple drugs was used on active TB, many TB
patients cannot complete a full period of treatment,
which lead to failure of treatment and acquired drug
resistance with eventual creation of multi-drug-
resistant TB (MDR-TB) [4]. Accordingly, effective
vaccines are needed in the face of failing drug treat-
ments, and this may include therapeutic vaccines.
Protective immunity against TB is largely attributed to a
cellular immune response in which the production of the
Th1-type cytokines (for example interferon-gamma, IFN-
γ) predominates over the production of the Th2-type
cytokines (for example interleukin-4, IL-4) [5–7]. DNA
vaccination has been found to establish and boost
antigen-specific cellular immunity in the direction of
responses. Furthermore, immunotherapy with plasmid
DNA has been found to be an effective adjunctive treat-
ment in combination with antibacterial chemotherapy in
mice. It both shortened the period of treatment and
improved the therapy outcome of latent TB infection
[8, 9]. Furthermore, we and others have shown that
ag85a DNA vaccine can also have immunotherapeutic
effects against MDR-TB in mice [10–12]. Here we re-
port that the rv2190c gene of Mycobacterium tubercu-
losis (MTB) is similarly effective as a therapeutic
DNA vaccine. The open reading frame (ORF) contains
1177 nucleotides and encodes a hypothetical protein
with an NlpC/P60 domain [13]. Målen et al. [14]
identified the protein product of rv2190c in MTB
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culture filtrate, showing that it could be expressed
and secreted in vitro. Parthasarathy et al. [15] showed
that the gene and its protein product were essential
for normal growth and virulence of MTB in vivo and
McMurry et al. [16] found that Rv2190c peptide
could stimulate peripheral blood mononuclear cells to
secrete IFN-γ in persons with latent TB infection.
Beyond that, MTB Rv2190c antigen has not been
extensively studied and thus therefore presents new
possibilities for developing drug targets, diagnostic
reagents and vaccines. Accordingly we evaluated its
immunogenicity and immunotherapeutic effects as a
DNA vaccine in mice.
Methods
Mice
One hundred 6-8 week age of female BALB/c mice
without specific pathogen were purchased from the
Academy of Military Medicine and Science, Beijing,
China, maintained under infection barrier conditions
in a negative pressure animal room in the 309th Hos-
pital of Chinese PLA, Beijing, China, and fed a sterile
commercial mouse diet (Beijing KeAoXieLi Company
Limited, China). The study procedures were approved
by the 309th Hospital of the Chinese PLA Research
Animal Ethics Committees.
MTB strain
MTB H37Rv was provided by National Institutes for
Food and Drug Control, Beijing, China.
Preparation of recombinant Rv2190c protein
The procedures preparation of Rv2190c protein were
briefly as follows: a 1168 bp gene fragment of rv2190c
was amplified by polymerase chain reaction (PCR). The
forward primer with a Nhe I enzyme site: 5′- CTAGCT
AGCATGAGGCTCGACCAGAGGTGGTT -3′; the re-
verse primer with an EcoR I enzyme site: 5′- CCGGAA
TTCTCAGTAACGGCGGGCGTCG -3′. The resulting
PCR product was ligated with plasmid vector pET30a
(Promega), and then transformed into E. coli DH5α [17].
The recombinant plasmid rv2190c/pET30a was analyzed
by Huada gene Ltd. Beijing, China and had 100% iden-
tity with the designed sequence by BLAST analysis. The
recombinant plasmid was transformed into E. coli strain
BL21 (DE3). The expression and purification of recom-
binant Rv2190c protein was performed according to the
method described previously [18].
Construction of rv2190c DNA vaccine
The construction map and method of rv2190c DNA vac-
cine were shown in Fig.1 and described previously [19].
The sequence encoding Rv2190c was amplified from
MTB H37Rv by PCR. The forward primer with a Nde I
enzyme site: 5′- CTAGGCTAGCCACCATGGGGCTCG
ACCAGAGGTGGTT-3′; the reverse primer with an
EcoR I enzyme site: 5′-CCGGAATTCTCA GTAACGGC
GGGCGTCG -3′ (synthesized by Shanghai Sangon Ltd.
Beijing, China). The PCR product fragment was
1177 bp. Recombinant plasmid rv2190c DNA was se-
quenced by Huada gene Ltd. Beijing, China and was
found to conform to the sequence designed using
BLAST analysis. EndoFree plasmid purification kit
(Qiagen, Hilden, Germany) was used to purify rv2190c
DNA vaccine.
Immunogenicity of rv2190c DNA vaccine
Fifty female BALB/c mice were divided into 5 groups as
follow: (1) saline as a negative control (100 μl); (2) vector
pVAX1 as a negative control (100 μg in 100 μl saline);
(3) M. vaccae (22.5 μg in 100 μl saline, Longcome
Biological Pharmacy, Anhui, China) as a positive control;
(4) ag85a DNA (100 μg in 100 μl saline), as a positive
control; (5) rv2190c DNA (100 μg in 100 μl saline),
immunized intramuscularly three times at two-week
intervals.
Cytokine production in vitro
The mice were sacrificed at three weeks after the third
immunization. The mouse splenocytes were isolated and
cultured (5 × 105 cells/well) with Ag85A or Rv2190c
protein (20 μg/ml) or phytohaemagglutinin (PHA;
20 μg/ml) for 72 h. The levels of IFN-γ and IL-4 in the
splenocytes culture supernatants were detected using
enzyme-linked immunosorbent assay (ELISA) kit (BD
PharMingen, San Diego, California, USA) according to
the manufacturer’s procedures.
Determination of CD4+ T cell subsets expressing
intracellular IFN-γ or IL-4
The operation procedure was described previously [20].
Briefly, Th1 and Th2 cells responding to Ag85A or
Rv2190c proteins were calculated. Cells expressing IFN-
γ and IL-4 were presented as a percentage of the total
population of CD3+ cells. The data were collected using
a fluorescence-activated-cell-sorting (FACS) Calibur flow
cytometer (BD Pharmingen) and analyzed using Cell-
Quest software.
Treatment of TB-infected mice
Fifty mice were challenged with 6.4 × 105 colony-
forming units (CFUs) of MTB H37Rv through trail vein
injection, randomly divided into five groups mentioned
above, and then treated at the third day after infection.
Bacterium counts
The mice were sacrificed by cervical dislocation under
anesthetic with 5 ml dethyl ether (Beijing Chemical
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Reagents Company, Beijing, China) at two weeks after the
third immunization. The tissue suspensions of mouse
lungs and spleens were serially diluted 10-fold, and 100 μL
suspension dilution were inoculated in duplicate on
Lowenstein-Jensen medium plates and cultured at 37 °C
for 4 weeks. MTB colonies on medium were counted and
the results were showed as CFUs per organ.
Lung histopathological examination
The mouse lungs tissues paraffin-embedded were sliced
into 3-μm thick tissue sections, which were dyed with
hematoxylin and eosin, and then examined by a certified
and veteran pathologist.
Statistical analyses
Data are shown as means and standard deviations.
Statistical analyses were performed using one-way
ANOVA followed by Dunnett’s multiple comparison
test, and a P-value of < 0.05 was considered as significant
difference.
Results
Preparations of rv2190c DNA and recombinant Rv2190c
protein
The nucleotide sequence in pVAX1-rv2190c plasmid
had 100% identity with MTB rv2190c sequence as
designed and the fragment size from restriction-enzyme-
Fig. 1 The construction map and gene sequence of rv2190c DNA. Black letters are the rv2190c gene sequence. The bold and underline letters are
the site of restrictive enzymes Nhe I and EcoR I. The double underline letters are the optimized gene sequence
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digested recombinant plasmid pVAX1-rv2190c was
1.177 kb on 0.8% agarose gel electrophoresis, and that
confirmed the successful construction (Additional file 1:
Figure S1).
The recombinant Rv2190c protein was soluble in
expression and amounted to 30% of total bacterial
protein. The molecular mass of the purified Rv2190c
protein was around 42 kDa by SDS-PAGE, its purity was
higher than 90% (Additional file 2: Figure S2).
Specific cytokine production levels in splenic lymphocyte
culture supernatants
The IFN-γ level in splenic lymphocyte culture superna-
tants in the rv2190c DNA group was obviously higher
than those in the saline, plasmid vector and M. vaccae
groups (P < 0.05), but had no significant difference from
that in the ag85a DNA group. The production of IL-4
was not significantly different between groups (Fig.2,
Additional file 3).
CD4+ T cell subsets expressing intracellular IFN-γ or IL-4
The proportion of CD4+ T cells expressing IFN-γ (Th1)
in response to Ag85A or Rv2190c proteins was signifi-
cantly higher in the whole blood from the rv2190c DNA
group than those from the saline group and vector
group by flow cytometry (P < 0.001), but there was no
significant difference from the M. vaccae group or ag85a
DNA group. The proportion of cells expressing IL-4
(Th2) was significantly higher in the blood from the
rv2190c DNA group than those from the control groups
(P < 0.05), but there was no significant difference from
the M. vaccae group or ag85a DNA group. Th1/Th2
ratio in the blood from the rv2190c DNA group was
significantly decreased than that in the ag85a DNA
group, and increased than those in the saline, vector and
M. vaccae groups, but the differences were not signifi-
cant (Fig. 3, Additional file 3).
Mouse survival
There was one mouse death in vector group, one in M.
vaccae group and one in rv2190c DNA group at 29 days
after infection (90% survival). The other mice were all
alive.
Bacterial counts in the lungs and spleens
The live bacteria in mouse lungs and spleens were deter-
mined at two weeks after third of immunotherapy. The
lung CFUs from saline, vector, M. vaccae, ag85a DNA
and rv2190c DNA groups were 7.334 ± 0.180, 7.233 ±
0.102, 7.081 ± 0.369, 6.801 ± 0.407 and 7.051 ± 0.154
log10, respectively (Fig.4a, Additional file 3), and the
spleen CFUs were 6.919 ± 0.117, 6.808 ± 0.067, 6.652 ±
0.345, 6.494 ± 0.211 and 6.598 ± 0.143 log10, respectively
(Fig.4b, Additional file 3). Compared with saline group,
rv2190c DNA and ag85a DNA decreased the lung CFUs
by 0.283 (P > 0.05) and 0.533 log10 (P < 0.05) and the
spleen CFUs by 0.321 and 0.425 log10 (P < 0.05),
respectively.
Histopathological changes
The lung sections from the saline group and plasmid
vector group showed extensive lung lesions, in which
hyperemia and congestion in alveoli with many lympho-
cytes and destructive structure caused by severe inflam-
mation. The lung sections from treatment groups
showed more foamy macrophages but less lymphocyte
infiltration, the alveoli were relatively clear and had nor-
mal structure. Representative histopathological changes
of five groups were shown in Fig.5.
Fig. 2 IFN-γ (a) and IL-4 (b) levels in the culture supernatants of splenocytes were detected by ELISA. The production of IFN-γ from rv2190c
DNA group was significantly higher than from the saline group, vector group and M. vaccae group (P < 0.05), but the production of IL-4 was
not significantly different between the groups
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Discussion
In this study, a DNA sequence encoding MTB Rv2190c
protein was inserted into plasmid vectors pET30a and
pVAX1, thereby recombinant Rv2190c protein and
rv2190c DNA vaccine were prepared and subsequently
used to compare the therapeutic effects of rv2190c DNA
with those of ag85a DNA as vaccines against TB in
mice.
The cellular immune responses to rv2190c DNA were
measured as increase in frequency of circulating T cells
that produced either IFN-γ or IL-4 in response to cog-
nate vaccine antigen since these cytokines are markers
of protective Th1 responses and non-protective Th2
responses respectively. A balance between Th1 and
Th2 in which Th1 predominates is essential for the
control of TB and mycobacterial infection in mice
and human [2, 4]. In this study, the significantly in-
creased IFN-γ level in the spleen lymphocyte culture
supernatant, the abundance of Th1 cells and elevatory
ratios of Th1 /Th2 cells in antigen-specifically
stimulated whole blood from the rv2190c DNA group
were all similar to the results obtained in the ag85a
DNA group. Thus both vaccines induced a predomin-
antly Th1 immune response [5, 12–14]. This finding
was consistent with evidence from McMurry et al.
[16] showing that Rv2190c peptide can induce IFN-γ
production in cells from persons with latent TB infec-
tion, and indicated a potential utility of Rv2190c anti-
gen in therapeutic vaccination.
When used to treat infected mice, rv2190c DNA vac-
cine did indeed reduce the numbers of live bacteria
found in the organs sampled after 6 weeks of treatment
when compared to control mice. However, the reduction
in lung bacterial load was small, not statistically signifi-
cant, and less than that obtained after ag85a DNA treat-
ment. In contrast, the reduction of load in the spleen
was significant, but again less than that observed after
ag85a DNA treatment. Apparently, although the
rv2190c protein enhanced antibacterial immunity it was
in this respect a less effective vaccine antigen than the
Fig. 3 Frequencies of CD4+ T cell subsets in whole blood assessed by flow cytometry. The data are expressed as the mean % ± standard
deviation. a Th1 cells expressing IFN-γ (IFN-γ-FITC); b Th2 cells expressing IL-4 (IL-4-PE); c The ratio of Th1/Th2 cell frequencies
Fig. 4 The numbers of live bacteria in lungs (a) and spleens (b) at six weeks after infection. Compared with the saline group, rv2190c DNA and
ag85a DNA reduced the pulmonary bacterial loads by 0.283 (P > 0.05) and 0.533 logs (P < 0.05) and the splenic bacterial loads by 0.321 (P < 0.05)
and 0.425 logs (P < 0.05), respectively
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Ag85A protein. Nevertheless, in a practical therapeutic
vaccine for human use, more than one antigen is likely
to be required and Rv2190c is clearly a candidate for
inclusion. The greater effects in spleen than in lung
suggest that the DNA vaccines were more active against
bacteria in extra-pulmonary sites than in the lung, but
whether this was due to differential effects on bacterial
dissemination, growth inhibition or killing was not
investigated. Although organ bacterial load is one of the
important indicators to evaluate curative effects on ani-
mal TB experiments [21], evaluation of the impact upon
pathology is also essential. Strikingly, the lesions in the
lungs of rv2190c DNA and ag85a DNA vaccinated
groups were similarly lessened, suggesting that rv2190c
DNA and ag85a DNA provided similarly efficient
immunotherapy for TB disease in this model.
Conclusions
We successfully constructed a MTB rv2190c DNA vaccine
that could induce Th1-type cellular immune reactions in
mice and had some immunotherapeutic effects on tuber-
culosis in mice. It may have potential for use in an immu-
notherapeutic DNA vaccine against TB.
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Additional file 1: Figure S1. Fragment sizes of restriction-enzyme-
digested recombinant plasmid pVAX1-rv2190c. 1. PCR amplification product
of the recombinant plasmid pVAX1-rv2190c colony; 2. The recombinant
plasmid pVAX1-rv2190c digested by restriction endonuclease Nhe I and EcoR
I; 3. Digest of the pVAX1 vector DNA with restriction endonuclease Nhe I
and EcoR I; 4. The recombinant plasmid pVAX1-rv2190c DNA digested by
restriction endonuclease EcoR I; 5. Digest of the pVAX1 Vector DNA with
restriction endonuclease EcoR I; M: DM5000 DNA Marker. (TIF 45 kb)
Additional file 2: Figure S2. Expression and purification of recombinant
Rv2190c protein as determined by SDS-PAGE electrophoresis. The gel was
subjected to electrophoresis followed by Coomassie blue staining. Lane M,
protein molecular weight marker. Lane 1, E. coli lysates engineered before
isopropylthiogalactopyranoside (IPTG) induction. Lane 2, E. coli lysates
engineered after induction with IPTG. Lane 3, the purified recombinant
Rv2190c protein. (TIF 39 kb)
Additional file 3: The Excel data file [FOLT] Figshare, [DOI:10.6084/
m9.figshare.4668148 and https://figshare.com/s/bd46c22986c673579bb6]
includes all datasets supporting the conclusions of this article: IFN-γ in
spleen lymphocyte culture supernatants, IL-4 in spleen lymphocyte culture
supernatants, CD4+ T cell subsets expressing intracellular IFN-γ or IL-4, CFU
in the lungs and spleens.. (XLS 143 kb)
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